DONADIO ANA CAROLINA
Congresos y reuniones científicas
Título:
Experimental Autoimmune Prostatitis (EAP). Analysis of Inflammatory Cells During the Development of the Lesion
Autor/es:
DONADIO AC, DEPIANTE DEPAOLI M.
Lugar:
Mendoza, Argentina.
Reunión:
Congreso; Reunión Científica de Invierno de la Sociedad Argentina de Inmunología; 1992
Institución organizadora:
Sociedad Argentina de Inmunología
Resumen:
Immunohistochemical procedures to analyze prostate infiltrating cells during EAP development was performed by indirect immunofluorescence test using mAbs. Rats were immunized with syngeneic male accesory glands (MAG) and complete Freund´s adjuvant on day 0 and 21 and their prostates were obtaines on days 7, 14, 21 and 28 after first immunization. Immhophenotypic analysis of macrophages labeled with MRC OX41, MRC OX42 and MRC OX43 mAbs did not show a high proportion of this cells in all periods studied. The staining with W3/25 (CD4) and MRC OX8 (CD8) showed acattered cells at day 7 and 14, while the proportion fo this cells increased notable at day 21 and 28. MRC OX6 mAb (anti IA) stained dispersed interstitial cells in all periods studied and ocassionally epithelial cells ( day 7 and 28). MRC OX17 mAb (anti IE) positivity in epithelial cells was evident in all periods analysed, except to day 14 , when a low intensity was observed. In control rats injectd with complete Freund´s adjuvant, we found scase labelled cells with the Abs used to reveal macrophages or T cells. The staining observed with anti Ia (IA and IE) antibodies does not differ to that obtained in normal rats.in wich cases wo observed a coger intensity and only zonal staining when it was compared with autoimmune rats. We could conclude that the development of the lesion in our experimental model is not straightly entailed with macrophages at the site of the injury. Instead the differential expresión of Ia and Ie antigens, with the presence of infiltrating lymphocytes could modulate the cellular immune response in the differential stages during the developmet of this autoimmune pathology.